Want to see FMC full AI Analyst Report?
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and profitability, and revealing strategic focus or potential vulnerabilities.Insecticides are the clear pressure point — a pronounced, multi-quarter decline driven largely by falling partner-related sales and the post‑patent transition (Rynaxypyr) plus India carve‑outs — while herbicides, fungicides and plant‑health show seasonal H2 strength and more stable branded demand. Management’s call confirms this picture: new actives and Isoflex EU approval offer genuine medium‑term upside, but near‑term recovery depends on successful H2 commercialization, $1B debt paydown and execution against generics and margin headwinds, so risk remains elevated despite improving momentum.
Date | Other | Insecticides | Herbicides | Fungicides | Plant Health |
|---|---|---|---|---|---|
Jun 30, 2026 | $700.00K | $423.50M | $318.20M | $88.40M | $36.30M |
Mar 31, 2026 | $700.00K | $340.60M | $313.70M | $55.80M | $47.80M |
Dec 31, 2025 | $58.20M | $440.30M | $378.80M | $140.40M | $65.60M |
Sep 30, 2025 | -$6.60M | $204.40M | $219.90M | $89.30M | $35.20M |
Jun 30, 2025 | $23.90M | $525.30M | $376.00M | $80.40M | $44.90M |
Mar 31, 2025 | $18.60M | $402.70M | $272.20M | $52.70M | $45.20M |
Dec 31, 2024 | $3.60M | $659.60M | $373.40M | $122.80M | $64.90M |
Sep 30, 2024 | $9.80M | $647.90M | $275.60M | $84.80M | $47.30M |
Jun 30, 2024 | $14.70M | $569.10M | $336.60M | $74.50M | $43.50M |
Mar 31, 2024 | $6.60M | $501.30M | $294.90M | $70.40M | $44.80M |